Ademi LLP is investigating Akili (Nasdaq: AKLI) for possible breaches of fiduciary duty and other violations of law in its transaction with Virtual Therapeutics.
In the transaction, Akili shareholders will receive only $0.4340 per share of common stock in cash. The transaction agreement unreasonably limits competing transactions for Akili by imposing a significant penalty if Akili accepts a competing bid. Akili insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Akili’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.